Vistagen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · Real-Time Price · USD

0.2600

-0.0076 (-2.84%)

At close: Aug 17, 2026, 4:00 PM EDT

0.2600

0.00 (0.00%)

Pre-market: Aug 18, 2026, 7:50 AM EDT

Vistagen Therapeutics Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	2.5	1.27	0.49	1.06	-0.23	1.11
Revenue Growth	287.15%	161.11%	-54.32%	-	-	1.78%
Gross Profit	2.5	1.27	0.49	1.06	-0.23	1.11
Selling, General & Admin	17.97	18.42	17.08	14.06	14.66	13.96
Research & Development	54.2	54.97	39.38	20.02	44.38	34.92
Operating Expenses	72.17	73.4	56.46	34.09	59.04	48.89
Operating Income	-69.67	-72.13	-55.97	-33.02	-59.27	-47.78
Interest & Investment Income	2.05	2.44	4.56	3.35	0.03	0.02
Other Non Operating Income (Expenses)	0.01	0.01	0.01	0.31	-	-
EBT Excluding Unusual Items	-67.61	-69.68	-51.41	-29.36	-59.24	-47.76
Pretax Income	-67.61	-69.68	-51.41	-29.36	-59.24	-47.76
Income Tax Expense	0.01	0.01	0.01	0	0.01	0
Net Income	-67.62	-69.69	-51.42	-29.36	-59.25	-47.76
Preferred Dividends & Other Adjustments	-	-	-	-	-	0.95
Net Income to Common	-67.62	-69.69	-51.42	-29.36	-59.25	-48.71
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	41	38	31	19	7	7
Shares Outstanding (Diluted)	41	38	31	19	7	7
Shares Change	30.85%	23.31%	59.53%	178.13%	5.45%	129.85%
EPS (Basic)	-1.66	-1.83	-1.67	-1.52	-8.51	-7.38
EPS (Diluted)	-1.66	-1.83	-1.67	-1.52	-8.51	-7.38
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-62.38	-66.59	-42.29	-25.87	-49.93	-45.46
Free Cash Flow Per Share	-1.53	-1.75	-1.37	-1.34	-7.17	-6.89
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	100.00%
Operating Margin	-2785.69%	-5683.69%	-11517.08%	-3103.48%	-	-4308.68%
Profit Margin	-2703.72%	-5491.33%	-10579.83%	-2759.59%	-	-4392.42%
Free Cash Flow Margin	-2494.32%	-5247.20%	-8701.24%	-2431.77%	-	-4099.28%
EBITDA	-69.46	-71.93	-55.82	-32.89	-59.14	-47.63
D&A For EBITDA	0.21	0.2	0.15	0.13	0.13	0.15
EBIT	-69.67	-72.13	-55.97	-33.02	-59.27	-47.78
Revenue as Reported	2.5	1.27	0.49	1.06	-0.23	1.11

SEC Filings: 10-K · 10-Q